复发性多形性胶质母细胞瘤的手术治疗:一项回顾性病例对照研究
该回顾性病例对照研究纳入174例成人初发异柠檬酸脱氢酶野生型胶质母细胞瘤患者,按年龄、性别和治疗匹配为87例复发后手术组与87例复发后未手术组。手术组总生存期(P=0.0003)和复发后生存期(P=0.001)均长于未手术组;复发时间>6个月者生存获益更显著(P<0.0001)。多因素分析显示复发后手术独立显著(P<0.0001)。
要点
- 复发后手术组总生存期较未手术组延长(P=0.0003)。
- 复发后手术组复发后生存期较未手术组延长(P=0.001)。
- 复发时间>6个月组生存较≤6个月组显著增加(P<0.0001)。
核心结论
- 复发性胶质母细胞瘤手术可改善生存,且独立于年龄、卡氏功能评分和肿瘤复发时间。
- 肿瘤复发时间>6个月的患者从再次手术中获益最大。
研究设计与样本
- 回顾性病例对照研究,回顾10年脑肿瘤数据库。
- 纳入174例成人(≥18岁)初发异柠檬酸脱氢酶野生型胶质母细胞瘤患者,复发后手术组87例与未手术组87例按年龄、性别和治疗匹配。
主要发现
- 手术组总生存期长于未手术组(P=0.0003)。
- 手术组复发后生存期长于未手术组(P=0.001)。
- 手术组内复发时间>6个月组生存较≤6个月组显著增加(P<0.0001)。
- 多因素分析调整年龄、卡氏功能评分和肿瘤复发时间后,复发后手术独立显著(P<0.0001)。
临床怎么用
- 作者认为复发性胶质母细胞瘤手术可改善生存,复发时间>6个月的患者获益最大。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The role of surgery in recurrent glioblastoma multiforme (GBM) remains a controversial topic. The goal of this study was to perform a case control analysis including time to tumor recurrence as an additional prognostic factor in order to determine which patients benefit most from repeat surgery. METHODS: Our brain tumor database was reviewed over a 10-year period for all adult (≥18 years old) patients with primary isocitrate dehydrogenase wildtype GBM who received surgery for recurrent disease. These patients were then age, sex, and treatment matched to case controls from our institution who received medical therapy for recurrent disease. RESULTS: A total of 174 adult patients with GBM were included in the study, 87 patients who received surgery for recurrent GBM (surgery cohort) and 87 patients who did not receive surgery for recurrent GBM (nonsurgery cohort). The surgery cohort had longer overall survival (P = 0.0003) and postrecurrence survival (P = 0.001) than the nonsurgery cohort. When the surgery cohort was split into 2 groups on the basis of time to tumor recurrence, the long time to recurrence group (>6 months) demonstrated significantly increased survival compared with the short time to recurrence group (P < 0.0001). Multivariate analysis of both cohorts demonstrated surgery for recurrent GBM was independently significant after adjusting for age, Karnofsky Performance Scale, and time to tumor recurrence (P < 0.0001). CONCLUSIONS: Surgery for recurrent GBM leads to improved survival independent of age, Karnofsky Performance Scale, and time to tumor recurrence. Patients with time to tumor recurrence >6 months benefit most from additional surgery.
引用
- Voisin MR, Zuccato JA, Wang JZ, et al. Surgery for Recurrent Glioblastoma Multiforme: A Retrospective Case Control Study. World Neurosurg. 2022. PMID: 35870781. doi:10.1016/j.wneu.2022.07.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。